XTX Topco Ltd Takes Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

XTX Topco Ltd bought a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 18,249 shares of the company’s stock, valued at approximately $100,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Sana Biotechnology by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after purchasing an additional 2,358,089 shares in the last quarter. Baillie Gifford & Co. grew its holdings in shares of Sana Biotechnology by 5.0% in the first quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock valued at $106,563,000 after purchasing an additional 506,262 shares in the last quarter. Capital World Investors increased its position in Sana Biotechnology by 255.8% in the first quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock worth $54,490,000 after purchasing an additional 3,917,728 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Sana Biotechnology by 2.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company’s stock valued at $36,956,000 after purchasing an additional 101,434 shares in the last quarter. Finally, Baker BROS. Advisors LP lifted its position in Sana Biotechnology by 19.0% during the first quarter. Baker BROS. Advisors LP now owns 2,380,949 shares of the company’s stock valued at $23,809,000 after purchasing an additional 380,949 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

Insiders Place Their Bets

In other news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 31.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. HC Wainwright decreased their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Citigroup upped their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research note on Wednesday, June 26th. They set a “buy” rating and a $16.00 target price for the company.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA opened at $4.24 on Wednesday. The business’s 50 day moving average is $5.09 and its 200 day moving average is $6.77. Sana Biotechnology, Inc. has a 52-week low of $2.74 and a 52-week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). On average, sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.13 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.